Berberine-Based Carbon Quantum Dots Improve Intestinal Barrier Injury and Alleviate Oxidative Stress in C57BL/6 Mice with 5-Fluorouracil-Induced Intestinal Mucositis by Enhancing Gut-Derived Short-Chain Fatty Acids Contents

Wu, Liang; Xi, Yue; Sun, Chang; Tan, Jiajun; He, Jiayuan; Li, Haitao; Wang, Dongxu

doi:10.3390/molecules28052148

Cited by 4 publications

(1 citation statement)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nucleotide-binding oligomerization domain-like receptor protein (NLRP) has many subtypes, such as NLRP1, NLRP3, NLRP6, and NLRC4 [ 40 ]. Our findings and those of other researchers show that NLRP3 inflammasome is one of the most studied cytoplasmic inflammasomes, and it plays a key role in the innate immune defense after infection by bacteria, fungi, and viruses, and its overactivation can participate in the occurrence and development of a variety of chronic diseases [ 41 , 42 ]. Studies have shown that the activation of NLRP3 inflammasome in the liver, skeletal muscle, and other tissues can significantly increase the risk of T2DM [ 43 , 44 ].…”

Section: Discussionsupporting

confidence: 73%

Inulin Reduces Kidney Damage in Type 2 Diabetic Mice by Decreasing Inflammation and Serum Metabolomics

He,

Li,

Yan

et al. 2024

Journal of Diabetes Research

Self Cite

View full text Add to dashboard Cite

This study is aimed at assessing the impact of soluble dietary fiber inulin on the treatment of diabetes-related chronic inflammation and kidney injury in mice with type 2 diabetes (T2DM). The T2DM model was created by feeding the Institute of Cancer Research (ICR) mice a high-fat diet and intraperitoneally injecting them with streptozotocin (50 mg/kg for 5 consecutive days). The thirty-six ICR mice were divided into three dietary groups: the normal control (NC) group, the T2DM (DM) group, and the DM + inulin diet (INU) group. The INU group mice were given inulin at the dose of 500 mg/kg gavage daily until the end of the 12th week. After 12 weeks, the administration of inulin resulted in decreased serum levels of fasting blood glucose (FBG), low-density lipoprotein cholesterol (LDL-C), blood urea nitrogen (BUN), and creatinine (CRE). The administration of inulin not only ameliorated renal injury but also resulted in a reduction in the mRNA expressions of inflammatory factors in the spleen and serum oxidative stress levels, when compared to the DM group. Additionally, inulin treatment in mice with a T2DM model led to a significant increase in the concentrations of three primary short-chain fatty acids (SCFAs) (acetic acid, propionic acid, and butyric acid), while the concentration of advanced glycation end products (AGEs), a prominent inflammatory factor in diabetes, exhibited a significant decrease. The results of untargeted metabolomics indicate that inulin has the potential to alleviate inflammatory response and kidney damage in diabetic mice. This beneficial effect is attributed to its impact on various metabolic pathways, including glycerophospholipid metabolism, taurine and hypotaurine metabolism, arginine biosynthesis, and tryptophan metabolism. Consequently, oral inulin emerges as a promising treatment option for diabetes and kidney injury.

show abstract

Section: Discussionsupporting

confidence: 73%

Inulin Reduces Kidney Damage in Type 2 Diabetic Mice by Decreasing Inflammation and Serum Metabolomics

He,

Li,

Yan

et al. 2024

Journal of Diabetes Research

Self Cite

View full text Add to dashboard Cite

show abstract

Effects of berberine on growth performance, intestinal microbial, SCFAs, and immunity for Ira rabbits

Lu,

Ye,

Jiang

et al. 2023

Preprint

View full text Add to dashboard Cite

Berberine (BBR), recognized for its anti-inflammatory and bactericidal properties, has been extensively studied for its effects on mammalian gut microbiota. This study specifically addresses the need for more research on the regulatory effects of BBR on the gut microbiota of Ira rabbits. To fill this gap, we administered varying concentrations of BBR to weaned Ira rabbits to assess its impact on their growth and gut microbiota. In our experiment, 245 healthy weaned rabbits, aged 33 days, were randomly assigned into five groups. The CG group received a standard diet, while groups I, II, III, and IV were given diets supplemented with BBR at doses of 5 mg/kg, 10 mg/kg, 20 mg/kg, and 40 mg/kg, respectively. A 7-day pre-feeding period was implemented for acclimatization, followed by a 30-day experimental phase. The results revealed that BBR significantly improved the Average Daily Feed Intake (ADFI) and Average Daily Gain (ADG) of the rabbits. Notably, group III showed a significantly higher final weight compared to other groups (P<0.05). BBR supplementation also increased serum levels of GSH-Px, SOD, and T-AOC, while decreasing MDA levels compared to the control group (P<0.05). It also upregulated pro-inflammatory mediators IL-1β, IL-6, and TNF-α, and downregulated anti-inflammatory mediators IL-10 and TGF-β1. Furthermore, BBR treatment led to a significant increase in Short-Chain Fatty Acids (SCFAs), specifically acetic and butyric acids (P<0.05). Regarding gut microbiota, BBR significantly enhanced the relative abundance of Bacteroidota and Verrucomicrobiota at the phylum level and reduced Firmicutes (P<0.05). At the genus level, there was a significant increase inAkkermansiaandAlistipesand a decrease inRuminococcus(P<0.05). Overall, BBR appears to promote the growth of Ira rabbits by enriching beneficial bacteria, modulating inflammatory mediators in the TLR4/NF-κB pathway, and reducing inflammation and oxidative stress. Among the tested dosages, 20 mg/kg BBR had the most substantial impact.

show abstract

The clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver disease: a meta-analysis and systematic review

Nie,

Li,

Huang

et al. 2024

J Transl Med

View full text Add to dashboard Cite

Background Non-alcoholic fatty liver disease (NAFLD) is becoming increasingly prevalent worldwide, emerging as a significant health issue on a global scale. Berberine exhibits potential for treating NAFLD, but clinical evidence remains inconclusive. This meta-analysis was conducted to assess the efficacy and safety of berberine for treating NAFLD. Methods This study was registered with PROSPERO (No. CRD42023462338). Identification of randomized controlled trials (RCTs) involved searching 6 databases covering the period from their initiation to 9 September 2023. The primary outcomes comprised liver function markers such as glutamyl transpeptidase (GGT), alanine transaminase (ALT), aspartate transaminase (AST), lipid indices including total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C), homeostasis model assessment for insulin resistance (HOMA-IR) and body mass index (BMI). Review Manager 5.4 and STATA 17.0 were applied for analysis. Results Among 10 RCTs involving 811 patients, berberine demonstrated significant reductions in various parameters: ALT (standardized mean difference (SMD) = − 0.72), 95% confidence interval (Cl) [− 1.01, − 0.44], P < 0.00001), AST (SMD = − 0.79, 95% CI [− 1.17, − 0.40], P < 0.0001), GGT (SMD = − 0.62, 95% CI [− 0.95, − 0.29], P = 0.0002), TG (SMD = − 0.59, 95% CI [− 0.86, − 0.31], P < 0.0001), TC(SMD = − 0.74, 95% CI [− 1.00, − 0.49], P < 0.00001), LDL-C (SMD = − 0.53, 95% CI [− 0.88, − 0.18], P = 0.003), HDL-C (SMD = − 0.51, 95% CI [− 0.12, 1.15], P = 0.11), HOMA-IR (SMD = − 1.56, 95% CI [− 2.54, − 0.58], P = 0.002), and BMI (SMD = − 0.58, 95% CI [− 0.77, − 0.38], P < 0.00001). Importantly, Berberine exhibited a favorable safety profile, with only mild gastrointestinal adverse events reported. Conclusion This meta-analysis demonstrates berberine's efficacy in improving liver enzymes, lipid profile, and insulin sensitivity in NAFLD patients. These results indicate that berberine shows promise as an adjunct therapy for NAFLD. Trial registration The protocol was registered with PROSPERO (No. CRD42023462338). Registered on September 27, 2023 Graphical Abstract

show abstract

Berberine-Based Carbon Quantum Dots Improve Intestinal Barrier Injury and Alleviate Oxidative Stress in C57BL/6 Mice with 5-Fluorouracil-Induced Intestinal Mucositis by Enhancing Gut-Derived Short-Chain Fatty Acids Contents

Cited by 4 publications

References 44 publications

Inulin Reduces Kidney Damage in Type 2 Diabetic Mice by Decreasing Inflammation and Serum Metabolomics

Inulin Reduces Kidney Damage in Type 2 Diabetic Mice by Decreasing Inflammation and Serum Metabolomics

Effects of berberine on growth performance, intestinal microbial, SCFAs, and immunity for Ira rabbits

The clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver disease: a meta-analysis and systematic review

Contact Info

Product

Resources

About